Rocket Report: SpaceX launch prices are going up; Russia fixes broken launch pad

NASA restructured the Artemis program by canceling a planned new upper stage for the Space Launch System in favor of a commercial upper stage—likely ULA’s Centaur—to reduce costs and remove near-term pressure to demonstrate cryogenic refueling; Artemis III will now be a low-Earth-orbit docking mission with Orion and commercial human-rated landers, while Artemis IV is slated as the first lunar landing attempt. Separately, the U.S. Air Force reaffirmed that the LGM-35A Sentinel ICBM is on track for a first test flight next year, intended to replace Minuteman III with initial operational capability in the early 2030s, though full deployment of 450 hardened silos will take longer.

Analysis

Market structure: NASA shifting from an agency-built SLS upper stage to a commercial Centaur-like stage is a win for large aerospace primes with existing cryogenic stage production (Lockheed Martin LMT, Northrop Grumman NOC indirectly via supply chains, Aerojet Rocketdyne AJRD for propulsion) and for ULA’s backlog. It reduces technological risk and capex for NASA, compresses R&D spending timelines, and likely creates multi-year production contracts that can translate to steady revenue growth of +$200–$500m/year across primes if award size mirrors past SLS/Orion subcontracts.

Risk assessment: Tail risks include a catastrophic SLS failure (program pause), Congress re-prioritizing budgets, or a commercial supplier production shortfall; any of these could wipe out 6–12 months of revenue for suppliers. Immediate market impact is muted (days), material contract updates and budget decisions will drive moves over 3–12 months, and the full revenue shift plays out over years (2026–2032) as Artemis IV becomes the first lunar landing attempt.

Trade implications: Favor large-cap defense/aerospace long exposures and avoid pure-play in-orbit refueling startups; expect fewer near-term contract wins for companies banking on cryogenic LEO refueling. Cross-asset: modest tightening of credit spreads for investment-grade defense names; little FX/commodity impact but higher implied vols on small-cap space names if awards disappoint.

Contrarian view: Consensus celebrates established primes, but the market underestimates concentration risk — relying on one commercial stage supplier creates single-point failure risk and potential renegotiation of margins. Also, vendors already trading rich on defense narratives (LMT, NOC) could disappoint if award sizes are smaller than assumed; historical parallel: shuttle-to-commercial pivot benefited nimble entrants (SpaceX) more than incumbents when incumbents failed to scale.

Key Decisions for Investors

• Establish a 1.5–2.5% portfolio long position in Lockheed Martin (LMT) using a 9–12 month horizon; prefer buying a 12-month call spread (buy 1 ATM call, sell 1.2x strike) to limit capital and target ~20–30% upside if NASA awards stage contracts within 6–12 months.
• Add a 1% tactical long in Aerojet Rocketdyne (AJRD) via outright stock or 9–12 month LEAP calls (delta ~0.4) to capture propulsion demand from both Artemis and Sentinel; trim on a 25% move higher or if contract language shows <50% propulsion content.
• Reduce exposure by 50% to small-cap/ETFs focused on in-orbit refueling and early-stage space startups (if any >2% avg position), reallocating proceeds to defense primes over the next 30 days as refueling timelines have been de-risked by NASA shifting to commercial upper stages.
• Implement a pair trade: long NOC (1%) and short a small-cap space launch name (e.g., small-cap pure-play launchers or an ETF overweight to them) for net market-neutral exposure; close or reassess within 6–9 months or when major contract awards are announced.
• Monitor three catalysts closely and act within windows: NASA contract award language (watch FedBizOpps/GSA within 3–6 months), DoD budget amendments around Pentagon hearings (next 6–12 months), and the first Sentinel test flight (expected next year) — if any catalyst misses expectations, reduce aerospace/defense long exposure by 30% within 5 trading days.